로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CD20

CD20

Check out full-length Claudin 18.2, CD20 and more.

요약

Name:B-lymphocyte antigen CD20
Target Synonym:B-lymphocyte surface antigen B1,MS4A1,B-lymphocyte antigen CD20,Membrane Spanning 4-Domains A1,Leukocyte Surface Antigen Leu-16,CD20 Antigen,CD20,Bp35,Membrane-Spanning 4-Domains Subfamily A Member 1,CD20 Receptor,LEU-16,CVID5,MS4A2,B1,S7,Antigens, CD20,Membrane-Spanning 4-Domains, Subfamily A, Member 1,B-Lymphocyte Cell-Surface Antigen B1
Number of Launched Drugs:23
Number of Drugs in Clinical Trials:81
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

CD0-H52H1-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc) (HEK293)(Cat. No. CD0-H52H1) and negative control protein respectively, washed and then followed by PE anti-His antibody and analyzed with FACS (QC tested).

CD0-H82E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of CD20-CAR-293 cells transfected with anti-CD20-scFv were stained with 100 μL of 3 μg/mL of Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

CD0-C52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Rituximab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 5.48 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

CD0-C52H8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Ofatumumab captured on CM5 chip via anti-human IgG Fc antibody can bind Cynomolgus CD20 Full Length, His Tag (Cat. No. CD0-C52H8) with an affinity constant of 3.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

사용자 리뷰

Synonym Name

MS4A1,CD20,MS4A-1

Background

B-lymphocyte antigen CD20  is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Rituximab biosimilar (Reliance Life Sciences) R-TPR-017 Approved Reliance Life Sciences Toritz, RituxiRel India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid null 2016-01-01 Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Center of Molecular Immunology) Approved Center Of Molecular Immunology CIMAbior, RituxCIM Cuba Lymphoma, Non-Hodgkin null 2017-04-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Biocad) BCD-020 Approved Biocad Acellbia Russian Federation Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin Biocad 2015-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
rituximab biosimilar (Zenotech) Approved Zenotech Laboratories India Lymphoma, Non-Hodgkin Zenotech Laboratories 2013-02-01 Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Intas Biopharmaceuticals) Approved Intas Biopharmaceuticals Mabtas India Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Intas Biopharmaceuticals 2013-01-01 Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Biosidus) Approved Biosidus Argentina Hematologic Neoplasms Biosidus 2013-06-01 Hematologic Neoplasms Details
Rituximab biosimilar (Hetero Drugs) Approved Hetero Drugs Maball, Mabura India Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Hetero Drugs 2015-01-01 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Probiomed) PBO-326 Approved Probiomed Kikuzubam Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (AryoGen Biopharma) Approved Aryogen Biopharma Zytux Iran Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis; Microscopic Polyangiitis Aryogen Biopharma 2014-01-01 Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Hyaluronidase/Rituximab Approved Genentech Inc Rituxan Hycela United States Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Genentech Inc 2017-06-22 Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Dr Reddy's Laboratories) Approved Dr Reddy's Laboratories Ltd Reditux, Tidecron India Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid Dr Reddy's Laboratories Ltd 2007-01-01 Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Shanghai Henlius Biotech) HLX-01 Approved Shanghai Henlius Biotech Co Ltd 汉利康 Mainland China Arthritis, Rheumatoid Shanghai Henlius Biotech Co Ltd 2019-02-22 Lymphoma, B-Cell; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Rituximab R-105; RG-105; IDEC-102; IDEC-C2B8; RO-452294 Approved Biogen Inc 美罗华, Ristova, Rituxan, MabThera, MabThera/Rituxan EU Burkitt Lymphoma; Lymphoma, Large B-Cell, Diffuse Roche Registration Gmbh 1997-11-26 Granulomatosis with Polyangiitis; Multiple Sclerosis, Relapsing-Remitting; Rejection of renal transplantation; Purpura, Thrombocytopenic, Idiopathic; Peripheral Nervous System Diseases; Lymphoma, B-Cell; Myasthenia Gravis; Polymyositis; HIV Infections; Hematologic Neoplasms; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Leukemia; Ocular Motility Disorders; Opsoclonus-Myoclonus Syndrome; Keratoconjunctivitis Sicca; Liver Cirrhosis, Biliary; Rejection of liver transplantation; Microscopic Polyangiitis; Nephrosis; Schizophrenia; Dermatomyositis; Myositis; Renal Insufficiency; Hemophilia A; Pulmonary Alveolar Proteinosis; Scleritis; Lymphoma, Large B-Cell, Diffuse; Arthritis, Rheumatoid; Sarcoidosis; Psychotic Disorders; Autoimmune Diseases; Purpura, Thrombotic Thrombocytopenic; Polyneuropathies; Idiopathic Pulmonary Fibrosis; Purpura; Plasmacytoma; Scleroderma, Systemic; Pemphigoid, Benign Mucous Membrane; Spondylitis, Ankylosing; Proteinuria; Sjogren's Syndrome; Neoplasms; Graft vs Host Disease; Details
Rituximab biosimilar (Pfizer) PF-05280586; PF-5280586 Approved Pfizer Pharmaceuticals Ltd (China) Ruxience EU Lymphoma, Non-Hodgkin; Pemphigus; Microscopic Polyangiitis; Leukemia, Lymphocytic, Chronic, B-Cell; Arthritis, Rheumatoid; Granulomatosis with Polyangiitis Pfizer Europe Ma Eeig 2019-07-23 Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus Details
Rituximab biosimilar (Amgen) APB-798; ABP-798 Approved Amgen Inc Riabni United States Arthritis, Rheumatoid Amgen Inc 2020-12-17 Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Arthritis, Rheumatoid; Lymphoma, Follicular; Plasmablastic Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (mAbxience) RTXM-83; mAbx-02 Approved Novex Argentina Lymphoma, Large B-Cell, Diffuse Mabxience 2015-01-01 Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Innovent Biologics) IBI-301 Approved Innovent Biologics(Suzhou) Co Ltd 达伯华, HALPRYZA Mainland China Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular Innovent Biologics(Suzhou) Co Ltd 2020-09-30 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Ofatumumab OMB-157; HuMax-CD2; GSK-1841157; 2F2 Approved Genmab Arzerra, Kesimpta Mainland China Multiple Sclerosis, Relapsing-Remitting Beijing Novartis Pharma Co Ltd 2009-10-26 Leukemia; Lymphoma, B-Cell, Marginal Zone; Multiple Sclerosis, Relapsing-Remitting; Leukemia, Lymphoid; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Multiple Sclerosis; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Lymphoma; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Celltrion) CT-P10 Approved Celltrion Truxima, Blitzima, Ritemvia, Rituzena United States Lymphoma, Non-Hodgkin Celltrion Inc 2017-02-17 Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell; Pemphigus; Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Arthritis, Rheumatoid; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Microscopic Polyangiitis; Leukemia, Lymphoid; Granulomatosis with Polyangiitis Details
Ibritumomab tiuxetan IDEC-In2B8; BAY86-5128; SHL-749; IDEC-129; IDEC-2B8-MX-DTPA; IDEC-Y2B8 Approved Biogen Inc Zevalin, Zavalin Japan Lymphoma, Non-Hodgkin; Lymphoma, Mantle-Cell Mundipharma Kk 2002-02-19 Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Mosunetuzumab RG-7828; BTCT-4465A; RO-7030816 Approved Genentech Inc Lunsumio EU Lymphoma, Follicular Roche Registration Gmbh 2022-06-03 Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin Details
Ocrelizumab R-1594; RG-1594; PRO-70769; RO-4964913; rhuMab 2H7 Approved Genentech Inc Ocrevus EU Multiple Sclerosis Roche Registration Gmbh 2017-03-28 Multiple Sclerosis, Relapsing-Remitting; Schizophrenia; Arthritis, Rheumatoid; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Lymphoma, Non-Hodgkin; Encephalitis Details
Obinutuzumab RG-7159; RG-7195; RO-5072759; B-HH6-B-KV1-GE; R-7159; GA-101; RG7159-7 Approved Genentech Inc Gazyva, Gazyvaro, Gazyva/Gazyvaro, 佳罗华 EU Lymphoma, Follicular F. Hoffmann-La Roche Ltd 2013-11-01 Lymphoma, Follicular; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Colorectal Neoplasms; Lymphoma, Mantle-Cell; Leukemia, Prolymphocytic, B-Cell; Glomerulosclerosis, Focal Segmental; Solid tumours; Lupus Nephritis; Glomerulonephritis, Membranous; Neoplasms; Graft vs Host Disease; Lymphoma, Large B-Cell, Diffuse; Anemia; Leukemia, Hairy Cell; Leukemia, Lymphoid; Nephrosis; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell Details
Rituximab biosimilar (Sandoz) GP-2013 Approved Sandoz Riximyo, Rixathon Japan Microscopic Polyangiitis; Lymphoma, Non-Hodgkin; Granulomatosis with Polyangiitis Clariant Produkte (Schweiz) Ag 2017-06-15 Granulomatosis with Polyangiitis; Lymphoma, B-Cell; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase 2 Clinical Southwest Hospital Chongqing Lymphoma, Large B-Cell, Diffuse Details
CD19/CD20 CAR-T Cell Therapy (PersonGen) Phase 1 Clinical Details
Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center, National Cancer Institute Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (International Biotech Center Generium) GNR-006 Phase 1 Clinical International Biotech Center Generium Lymphoma, B-Cell Details
Rituximab biosimilar (Gedeon Richter) RGB-03 Phase 1 Clinical Gedeon Richter Arthritis, Rheumatoid Details
Anti-CD20 CART-transduced T cells (Cellular Biomedicine Group) CART-20; CBM-C20.1; CBM-CD20 1 Phase 2 Clinical Pla General Hospital Leukemia; Lymphoma, B-Cell Details
Bendamustine Hydrochloride/Rituximab Phase 1 Clinical 1globe Biomedical Co Ltd Lymphoma, B-Cell Details
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) Phase 2 Clinical Shenzhen University General Hospital Lymphoma, B-Cell Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase 1 Clinical Henan Provincial Cancer Hospital Lymphoma, B-Cell Details
Anti-CD20 CAR T-cell therapy (Shanghai Longyao Biotechnology) Phase 2 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse Details
Anti-CD20 CAR-T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Neoplasms Details
Rituximab biosimilar (Hisun Pharma/Beijing Mabworks Biotech) Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Recombinant anti-CD20 chimeric monoclonal antibody (Livzon Group) LZM-002 Phase 1 Clinical Livzon Pharmaceutical Group Inc Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Fred Hutchinson Cancer Research Center) Phase 1 Clinical Fred Hutchinson Cancer Research Center Multicentric Castleman's Disease (MCD); Sarcoma, Kaposi Details
ADI-001 ADI-001 Phase 1 Clinical Adicet Bio Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Burkitt Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar(Shandong New Time Pharmaceutical) H-02; F-007 Phase 3 Clinical Shandong New Time Pharmaceutical Co Ltd Lymphoma, Large B-Cell, Diffuse Details
JMT-601 JMT-601 Phase 1 Clinical Shanghai Jinmante Biological Technology Co Ltd Lymphoma, Non-Hodgkin Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase 1 Clinical Uclas Jonsson Comprehensive Cancer Center Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab Biosimilar (Istituto Giannina Gaslini) Phase 2 Clinical Istituto Giannina Gaslini Nephrotic Syndrome Details
EX-103 EX-103; EX103 Phase 1 Clinical Guangzhou ASM Biomedical Technology Co Ltd Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
TanCART19/20 Phase 1 Clinical The General Hospital Of The People'S Liberation Army Neuromyelitis Optica Details
SNG2005 SNG-2005 Phase 1 Clinical Alopexx Oncology Lymphoma, B-Cell Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Lymphoma, B-Cell; Leukemia, B-Cell Details
LY007 LY007 Phase 1 Clinical Shanghai Longyao Biological Technology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin Details
TQB-2825 TQB-2825 Phase 1 Clinical Wuxi Biologics Co Ltd Hematologic Neoplasms; Neoplasms Details
Rituximab biosimilar(Bioxpress) BXT-2336 Clinical Bioxpress Therapeutics Sa Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Arthritis, Rheumatoid; Lymphoma, Non-Hodgkin; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell Details
Recombinant chimeric anti-CD20 antibody (Shanghai Institute of Biological Products) Phase 3 Clinical Shanghai Institute Of Biological Products Co Ltd Lymphoma, Large B-Cell, Diffuse Details
BVX20-CD20 antibody (Biocon/Vaccinex) BVX-20; BVX20-MAb Phase 2 Clinical Biocon, Vaccinex Lymphoma, Non-Hodgkin Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) CAR-20/19-T cells Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Crosslink Pharmaceutical) B-007 Phase 1 Clinical Shanghai Crosslink Pharmaceutical R & D Co Ltd Lymphoma, Non-Hodgkin Details
ACE-1831 ACE-1831 Phase 1 Clinical Acepodia Biotech Inc Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Details
Rituximab biosimilar (Lonza/Teva Pharmaceutical Industries) TL-011 Teva Pharmaceutical Industries, Lonza Details
CD20/CD22 dual Targeted CAR T-cell therapy (Zhejiang University) Zhejiang University Details
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) Phase 1 Clinical First Affiliated Hospital Of Zhejiang University Lymphoma, Large B-Cell, Diffuse Details
C-CAR039 EXP-039; C-CAR039; C-CAR-039 Phase 1 Clinical Cellular Biomedicine Group Ltd Lymphoma, Non-Hodgkin Details
Anti-CD20 CAR-T cell therapy (Beijing Biohealthcare Biotechnology) Beijing Biohealthcare Biotechnology Co Ltd Details
CPO-107 Conjupro Biotherapeutics Inc Details
QLP-31907 QLP-31907; QLP31907; PSB-202 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Lymphoma, B-Cell Details
CM-355(Beijing Tiannuo Jiancheng/Connaught Biomedical Technology) CM-355 Phase 2 Clinical Beijing Tiannuo Jiancheng Pharmaceutical Technology Co Ltd, Keymed Biosciences Co Ltd Hematologic Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin Details
MRG001 MRG-001 Phase 1 Clinical Shanghai Miracogen Inc Lymphoma, Non-Hodgkin Details
KITE-363 KITE-363 Phase 1 Clinical Kite Pharma Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse Details
CD20 CAR-T cell therapy (Shanghai Longyao Biotechnology) Shanghai Longyao Biological Technology Co Ltd Details
CD20-directed CAR-T cell therapy (Tongji Hospital) C-CAR066 Phase 1 Clinical Tongji Hospital Lymphoma, B-Cell Details
Allogeneic anti-CD20 CAR-T cell therapy (Precision BioSciences) PBCAR-20A Precision Biosciences Inc Details
IMM-0306 IMM-0306 Phase 1 Clinical Lymphoma, B-Cell Details
Eramkafusp alfa IGN-002 Immunogen Details
BAT-4406F BAT-4406; BAT-4406F Phase 1 Clinical Bio-Thera Solutions Ltd Neuromyelitis Optica Details
Recombinant anti-CD20 humanized monoclonal antibody (Shanghai Pharma) B001 Phase 1 Clinical Shanghai Pharmaceuticals Holding Co Ltd Neuromyelitis Optica; Lymphoma; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (BioIntegrator) Biointegrator Details
Ocrelizumab biosimilar (CinnaGen) Cinnagen Details
ACTR-707 ACTR-707 Unum Therapeutics Details
Divozilimab BCD-132 Biocad Details
SBI-087 SBI-087; PF-5230895; PF-05230895 Emergent Details
Rituximab conjugate (BioIntegrator) CON-4619 Biointegrator Details
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) Fujian Medical University Details
PRO-131921 PRO-131921 Genentech Inc Details
TRS-005 TRS-005 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma, Non-Hodgkin Details
Recombinant humanized monoclonal antibody MIL62 MIL62 Phase 3 Clinical Beijing Innocare Pharma Tech Co Ltd, Beijing Mabworks Biotech Co Ltd Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Nephrosis; Lupus Nephritis; Lymphoma, Follicular Details
MT-3724 MT-3724 Molecular Partners Ag Details
Recombinant Fc-glycosylated anti-CD20 monoclonal antibody (Bio-Thera Solutions) BAT-4306F Phase 1 Clinical Bio-Thera Solutions Ltd Lymphoma, Non-Hodgkin Details
Veltuzumab hA20; IMMU-106 Immunomedics Inc Details
MK-8808 MK-8808 Merck & Co Inc Details
Imvotamab IGM-2323 Igm Biosciences Inc Details
Rituximab biosimilar (Hualan Biological Engineering) WBP-263 Phase 3 Clinical Hualan Genetic Engineering Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Rituximab biosimilar (Genor Biopharma) GB-241 Phase 3 Clinical Genor Biopharma Co Ltd, Nanjing Yoko Biomedical Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Anti-CD20 allogeneic CAR-T cell therapy (Nanjing Medical University) LUCAR-20S Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (CTTQ Pharma) TQB-2303 Phase 3 Clinical Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Burkitt Lymphoma Details
Rituximab biosimilar (Boehringer Ingelheim) BI-695500 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Lymphoma, B-Cell; Leukemia, Lymphoid; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab biosimilar (Samsung) SAIT-101 Phase 1 Clinical Samsung Biologics Lymphoma, B-Cell; Leukemia, Lymphoid; Arthritis, Rheumatoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CAR-20-19-22 CAR-20-19-22 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
JS-203 JS-203 Phase 1 Clinical Shanghai Junshi Biological Engineering Co Ltd Lymphoma, B-Cell Details
Rituximab biosimilar (Zhejiang Teruisi Pharmaceutical) TRS001 Phase 1 Clinical Zhejiang Teruisi Pharmaceutical Inc Lymphoma Details
MB-CART20.1 (Miltenyi Biotec) Phase 1 Clinical Miltenyi Biotec Melanoma Details
MB-106 MB-106 Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Lymphoma, Mantle-Cell; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell Details
Rituximab/Paclitaxel AR-160 Phase 2 Clinical Mayo Clinic Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Plamotamab XmAb-13676 Phase 2 Clinical Xencor Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
MB-CART19.1 (Miltenyi Biotec) Phase 2 Clinical Miltenyi Biotec Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Zamtocabtagene autoleucel MB-CART2019.1 Phase 2 Clinical Miltenyi Biotec Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin Details
Chimeric antigen receptor T-cell therapy (Fred Hutchinson Cancer Research Center) Phase 2 Clinical Fred Hutchinson Cancer Research Center Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
Odronextamab REGN-1979 Phase 3 Clinical Regeneron Pharmaceuticals Inc Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Lymphoma, B-Cell; Leukemia, B-Cell Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases Details
GB-261 GB-261 Phase 2 Clinical Genor Biopharma Co Ltd Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
UCART-20x22 UCART-20x22 Phase 1 Clinical Cellectis Lymphoma, Non-Hodgkin Details
Glofitamab RG-6026; RO-7082859 Phase 3 Clinical F. Hoffmann-La Roche Ltd Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma Details
1-A-46 1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 Phase 2 Clinical Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) Phase 1 Clinical Shanghai Cellular Biopharmaceutical Group Ltd Lymphoma, B-Cell Details

This web search service is supported by Google Inc.

totop